Acta Pharmaceutica Sinica B

Scope & Guideline

Publishing Tomorrow's Pharmaceutical Breakthroughs Today

Introduction

Delve into the academic richness of Acta Pharmaceutica Sinica B with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2211-3835
PublisherINST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
Support Open AccessYes
CountryChina
TypeJournal
Converge2012, from 2014 to 2024
AbbreviationACTA PHARM SIN B / Acta Pharm. Sin. B
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressC/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING 100050, PEOPLES R CHINA

Aims and Scopes

Acta Pharmaceutica Sinica B is a leading journal that focuses on the intersection of pharmaceutical sciences and biotechnology, emphasizing innovative drug discovery, development, and delivery methods. The journal aims to publish high-quality research that advances the understanding of medicinal chemistry, pharmacology, and therapeutic applications.
  1. Drug Discovery and Development:
    The journal covers innovative approaches in drug discovery, including small molecules, biologics, and traditional medicines, emphasizing their mechanisms of action and therapeutic potential.
  2. Nanomedicine and Drug Delivery Systems:
    Significant focus on nanotechnology for drug delivery, exploring the design, synthesis, and application of nanocarriers to enhance therapeutic efficacy and reduce side effects.
  3. Pharmacology and Toxicology:
    Research on the pharmacokinetics, pharmacodynamics, and toxicological evaluations of new drugs, providing insights into their safety and efficacy profiles.
  4. Biotechnology and Molecular Biology:
    Studies that leverage biotechnological advancements, including CRISPR and gene editing, for therapeutic purposes, particularly in cancer and genetic diseases.
  5. Phytochemistry and Natural Products:
    Exploration of bioactive compounds from natural sources, including their pharmacological effects, mechanisms of action, and potential for drug development.
  6. Clinical Translational Research:
    Research that bridges laboratory findings with clinical applications, focusing on the development of new therapeutic strategies and improving patient outcomes.
Acta Pharmaceutica Sinica B has seen a surge in research themes that reflect the latest trends and advancements in pharmaceutical sciences. These emerging scopes indicate a shift towards innovative methodologies and therapeutic strategies.
  1. Immunotherapy and Checkpoint Inhibition:
    Research focusing on immunotherapy, especially combination therapies that enhance immune response against tumors, has gained significant traction, indicating a paradigm shift in cancer treatment.
  2. Nanomedicine Innovations:
    There is a growing trend in the development of novel nanomedicine platforms for targeted drug delivery, including stimuli-responsive systems that enhance therapeutic efficacy and minimize side effects.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene-editing technologies in drug development and disease treatment has emerged as a prominent theme, highlighting the potential for genetic therapies.
  4. Microbiome Research:
    Studies exploring the role of the gut microbiome in drug metabolism and therapeutic responses are gaining importance, reflecting a broader interest in personalized medicine.
  5. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is becoming increasingly prevalent, showcasing efforts to improve efficiency and accuracy in identifying potential drug candidates.
  6. Sustainable and Green Chemistry:
    Research emphasizing sustainable practices in drug development, including the use of renewable resources and eco-friendly processes, is on the rise, aligning with global sustainability goals.

Declining or Waning

While Acta Pharmaceutica Sinica B continues to thrive in numerous research areas, certain themes have shown signs of declining interest or publication frequency. These waning scopes reflect shifts in research focus and the evolving landscape of pharmaceutical sciences.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused on traditional drug formulations, as research shifts toward novel delivery systems and advanced drug formulations.
  2. Conventional Chemotherapy Approaches:
    The focus on conventional chemotherapy methods is waning in favor of targeted therapies and immunotherapies, indicating a shift toward more personalized medicine.
  3. Basic Pharmacognosy Studies:
    Research specifically centered on pharmacognosy without the application of modern techniques or translational potential has decreased, as the field moves towards integrating pharmacognosy with molecular biology.
  4. Single-Drug Therapy Studies:
    The decline in publications focusing solely on single-drug therapies suggests a growing interest in combination therapies and multi-target approaches to enhance treatment efficacy.

Similar Journals

Pakistan Journal of Pharmaceutical Sciences

Innovating the future of drug development and science.
Publisher: UNIV KARACHIISSN: 1011-601XFrequency: 4 issues/year

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

Indian Journal of Pharmaceutical Education and Research

Bridging local insights with global pharmaceutical advancements.
Publisher: ASSOC PHARMACEUTICAL TEACHERS INDIAISSN: 0019-5464Frequency: 4 issues/year

Indian Journal of Pharmaceutical Education and Research, published by the Association of Pharmaceutical Teachers of India, is a pivotal platform for scholarly discussion in the field of pharmacology, toxicology, and pharmaceutics. ISSN 0019-5464, this esteemed journal aims to foster the exchange of innovative research, clinical advancements, and educational practices within the pharmaceutical sciences community. As a Q3-ranked journal in its category as of 2023, it reflects a commitment to upholding the standards of academic excellence and contributes significantly to the ongoing development of pharmaceutical education. The journal is a valuable resource for researchers, professionals, and students, with content spanning various key areas including drug formulation, safety, and the latest trends in pharmaceutical education. By providing open access to its research and reviews, the journal ensures that vital information is disseminated widely, promoting collaboration and learning among stakeholders in the pharmaceutical sector. Based in Bangalore, India, the journal has been instrumental in highlighting regional research while fostering a global dialogue in pharmaceutical sciences. As it continues its journey from 2008 to 2024, it remains dedicated to impacting the field through rigorous peer-reviewed content and engaging with contemporary challenges in healthcare and education.

CURRENT PHARMACEUTICAL DESIGN

Exploring Breakthroughs in Pharmacology and Drug Design
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Future Journal of Pharmaceutical Sciences

Empowering Collaboration in Pharmaceutical Research
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Pioneering research at the intersection of science and care.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

DARU-Journal of Pharmaceutical Sciences

Advancing pharmaceutical knowledge for a healthier tomorrow.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Journal of Reports in Pharmaceutical Sciences

Elevating Standards in Pharmaceutical Research and Education.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

ACTA PHARMACEUTICA

Fostering collaboration through open-access research excellence.
Publisher: SCIENDOISSN: 1330-0075Frequency: 4 issues/year

ACTA PHARMACEUTICA is a distinguished open-access journal published by SCIENDO, dedicated to advancing knowledge in the fields of medicine and pharmaceutical sciences. Established in 1992, the journal has made significant contributions to the scholarly community, providing a platform for innovative research and discussion. With a strong presence in both Q2 and Q3 quartiles across various categories including Pharmaceutical Science and Pharmacology, ACTA PHARMACEUTICA ranks favorably, positioning its contributions in the upper tiers of the field. The journal's commitment to open access since 2007 ensures that both practitioners and scholars have immediate access to cutting-edge developments, thereby fostering collaboration and knowledge sharing. With its scope spanning a broad spectrum of pharmaceutical and biomedical research, ACTA PHARMACEUTICA is an essential resource for researchers, professionals, and students keen to stay abreast of the latest advancements and trends in these vital areas of study.

DRUG DEVELOPMENT RESEARCH

Unveiling breakthroughs in drug development for a healthier tomorrow.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

SCIENTIA PHARMACEUTICA

Advancing pharmaceutical science for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.